Connor, Clark & Lunn Investment Management Ltd. Citius Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 10, 2022	SELL	$1.51 - $2.2 $260,834 - $380,023	-172,738 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.74 - $2.6 $300,564 - $449,118	172,738 New	172,738 $351,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

23.7M

Call Options Held

83.1K

Put Options Held

32.1K

Armistice Capital, LLC New York, NY

7.28M
Shares

$18.7 Million
0.06% of portfolio
Vanguard Group Inc Valley Forge, PA

6.44M
Shares

$16.6 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

1.88M
Shares

$4.83 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.81M
Shares

$4.64 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.16M
Shares

$2.98 Million
0.0% of portfolio

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $376M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account